i2o Therapeutics has established collaborations with industry leaders to continue to push the frontier of oral therapeutics.
R&D collaboration and option agreement with Janssen to investigate the oral delivery of macromolecules. Read More ›
R&D collaboration with Sanofi to identify bespoke IL-nanobody combinations to enhance systemic exposure after oral dosing. Read More ›
Collaboration with Colorcon to advance ionic liquid technology for enhancing small molecule oral delivery. Read More ›
We welcome the opportunity to engage with new partners across all therapeutic areas. For partnership inquiries, please contact: bd@i2obio.com.